Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jul 4;2(3):22.
doi: 10.3390/jof2030022.

Galactomannan and 1,3-β-d-Glucan Testing for the Diagnosis of Invasive Aspergillosis

Frédéric Lamoth  1
Affiliations
Review

Galactomannan and 1,3-β-d-Glucan Testing for the Diagnosis of Invasive Aspergillosis

Frédéric Lamoth. J Fungi (Basel). .

Abstract

Invasive aspergillosis (IA) is a severe complication among hematopoietic stem cell transplant recipients or patients with hematological malignancies and neutropenia following anti-cancer therapy. Moreover, IA is increasingly observed in other populations, such as solid-organ transplant recipients, patients with solid tumors or auto-immune diseases, and among intensive care unit patients. Frequent delay in diagnosis is associated with high mortality rates. Cultures from clinical specimens remain sterile in many cases and the diagnosis of IA often only relies on non-specific radiological signs in the presence of host risk factors. Tests for detection of galactomannan- (GM) and 1,3-β-d-glucan (BDG) are useful adjunctive tools for the early diagnosis of IA and may have a role in monitoring response to therapy. However, the sensitivity and specificity of these fungal biomarkers are not optimal and variations between patient populations are observed. This review discusses the role and interpretation of GM and BDG testing for the diagnosis of IA in different clinical samples (serum, bronchoalveolar lavage fluid, cerebrospinal fluid) and different groups of patients (onco-hematological patients, solid-organ transplant recipients, other patients at risk of IA).

Keywords: ">d-glucan; 1,3-β-; Aspergillus fumigatus; fungal biomarkers; galactomannan; invasive aspergillosis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Proposed algorithm for the use of galactomannan (GM) and 1,3-β-d-glucan (BDG) testing for the diagnosis of invasive aspergillosis (IA) in clinical practice. Based on the following parameters: (1) prevalence of IA in a given population and (2) assessment of the clinical signs and symptoms of IA in a given patient, the clinician may establish the individual pre-test probability on a scale from low to high. While testing of GM and/or BDG may be useful in cases with moderate-high pre-test probability (by changing the post-test probability), interpretation of a positive or negative test is often inconclusive in low risk settings. HSCT: hematopoietic stem cell transplantation. Yellow circles: + positive test, - negative test.
See this image and copyright information in PMC

References

    1. Kontoyiannis D.P., Marr K.A., Park B.J., Alexander B.D., Anaissie E.J., Walsh T.J., Ito J., Andes D.R., Baddley J.W., Brown J.M., et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: Overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin. Infect. Dis. 2010;50:1091–1100. doi: 10.1086/651263. - DOI - PubMed
    1. Garbino J., Fluckiger U., Elzi L., Imhof A., Bille J., Zimmerli S. Survey of aspergillosis in non-neutropenic patients in Swiss teaching hospitals. Clin. Microbiol. Infect. 2011;17:1366–1371. doi: 10.1111/j.1469-0691.2010.03402.x. - DOI - PubMed
    1. Pappas P.G., Alexander B.D., Andes D.R., Hadley S., Kauffman C.A., Freifeld A., Anaissie E.J., Brumble L.M., Herwaldt L., Ito J., et al. Invasive fungal infections among organ transplant recipients: Results of the Transplant-Associated Infection Surveillance Network (TRANSNET) Clin. Infect. Dis. 2010;50:1101–1111. doi: 10.1086/651262. - DOI - PubMed
    1. De Pauw B., Walsh T.J., Donnelly J.P., Stevens D.A., Edwards J.E., Calandra T., Pappas P.G., Maertens J., Lortholary O., Kauffman C.A., et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 2008;46:1813–1821. - PMC - PubMed
    1. Marchetti O., Lamoth F., Mikulska M., Viscoli C., Verweij P., Bretagne S. ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. Bone Marrow Transplant. 2012;47:846–854. doi: 10.1038/bmt.2011.178. - DOI - PubMed